Stamulumab (MYO-029) is a recombinant human IgG1?? antibody designed to selectively bind to myostatin, effectively neutralizing its activity. This inhibition is achieved by preventing myostatin from interacting with its high-affinity receptor, ActRIIB. The primary biological outcome observed with Stamulumab treatment is muscle fiber hypertrophy, rather than hyperplasia, as demonstrated in SCID mice studies. Given its mechanism of action, Stamulumab is a valuable tool for research into various muscular dystrophies, including Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD), offering potential insights into therapeutic strategies targeting muscle growth and repair.
Stamulumab (MYO-029) is a recombinant human IgG1?? antibody designed to selectively bind to myostatin, effectively neutralizing its activity. This inhibition is achieved by preventing myostatin from interacting with its high-affinity receptor, ActRIIB. The primary biological outcome observed with Stamulumab treatment is muscle fiber hypertrophy, rather than hyperplasia, as demonstrated in SCID mice studies. Given its mechanism of action, Stamulumab is a valuable tool for research into various muscular dystrophies, including Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD), offering potential insights into therapeutic strategies targeting muscle growth and repair.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
